Across TCGA pan-cancer cohorts, C19orf54 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C19orf54 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher C19orf54 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C19orf54 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, READ, and BLCA are the cancer types where C19orf54 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.023	0.533	<.001	18	view →
READ	DFS	Median	All	0.112	0.845	.001	12	view →
BLCA	DFS	Median	III,IV	0.184	0.574	.016	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
UCEC	DFS	Median	All	1.000	0.631	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: C19orf54 tumor-vs-normal RNA expression · all C19orf54 data types